Analysis of the Incidence of Cholangiocarcinoma on Choledochal Cyst in a Western Center (QuiCo)

Choledochal cysts are congenital cystic dilatations of the intra and/or extrahepatic bile duct. They have been considered a rare entity of the child population. Globally, they account for 1% of all biliary pathology benign, with a clearly higher incidence in Asian countries (1/5,000 in China, 1/1,000 in Japan, compared to 1/100,000-150,000 in Western countries). However, the number of adults diagnosed in recent years has increased by up to 70% due to improvements in imaging tests.

Currently, the common bile duct malformation is considered a premalignant entity: although the data are not very precise, it is estimated that between 2.6% and 26% of patients diagnosed choledochal cyst, will develop cholangiocarcinoma. In this sense, we must bear in mind that most of the published literature is of Asian origin, where the rate of cholangiocarcinoma is 0.1-71/100,000 compared to 0.1-1.8/100,000 in Europe or 0.6-1/100,000 in the USA.

The most used classification to differentiate the types of cysts is that of Todani. Following this classification, we would find a higher rate of malignancy on types I and IV.

The recommendations found in the literature refer to the need for surgical intervention for choledochal cysts due to their high rate of malignancy. These recommendations are based on studies conducted in a symptomatic Asian population. We do not usually find in therapeutic algorithms the inclusion of various factors that could be involved in the development of malignancy such as episodes of cholangitis, presence of anomaly in the pancreatobiliary junction, presence of lithiasis in cystic dilatation, etc.

Some surveys carried out among the scientific population reflect a lack of consensus on its management: in the same clinical situation, different surgery units specialized in hepatobiliary-pancreatic pathology would act in the opposite way (specifically surgical versus conservative treatment).

Bile duct resection is not without complications, both short-term and long-term. Therefore, the patient's symptoms, age or comorbidities can play an important role in decision-making in the treatment of this pathology.

This nationwide multicenter retrospective observational study aims to determine the clinical situation of this rare pathology in a Western environment.

A retrospective analysis of patients diagnosed with choledochal cyst in the period between 2000 and 2020 is proposed. Demographic variables, risk factors for cholangiocarcinoma, symptoms associated with the cyst and its characteristics, diagnostic method, type of treatment, complications will be analyzed. Malignancy, time, and follow-up method will also be discussed.

This study will attempt to answer questions about the incidence of choledochal cysts in our environment, their association with cholangiocarcinoma, the associated morbidity and mortality, as well as the therapeutic and follow-up attitudes adopted in the face of this rare pathology.

Study Overview

• Status: Enrolling by invitation
• Conditions: Incidence of Cholangiocarcinoma on Choledochal Cysts; Postoperative Complications in Choledochal Cysts; Choledochal Cyst Monitoring

• Study Type: Observational
• Enrollment (Estimated): 300

Contacts and Locations

Study Locations

• Spain
  • Huelva, Spain, 21005
    • Juan Ramon Jimenez Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients with a radiological diagnosis of choledochal cyst. Those patients diagnosed by the radiology service are included

Description

Inclusion Criteria:

- A radiological diagnosis (diagnosed by the radiology service) of choledochal cyst, understood as a dilatation of the extra or intrahepatic bile duct (fusiform or saccular, following the Todani classification)

Exclusion Criteria:

• An objectified obstructive cause that justifies a dilatación of bile duct (lithiasis, papillitis or neoplasia)
• A definitive imaging test that rules out an initial diagnosis of choledochal cyst.
• Intraoperative diagnosis of choledochal cyst without subsequent radiological confirmation.
• Patients with cystic lesions of another nature (biliary cysts, simple cysts, cystic neoplasms).

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Choledochal cyst and cholangiocarcinoma	to analyze the incidence of cholangiocarcinoma in choledochal cysts	20 years

Collaborators and Investigators

• Sponsor: María Teresa Moreno Asencio

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2022
• Primary Completion (Actual): January 1, 2025
• Study Completion (Estimated): December 1, 2026

Study Registration Dates

• First Submitted: May 31, 2022
• First Submitted That Met QC Criteria: May 31, 2022
• First Posted (Actual): June 3, 2022

Study Record Updates

• Last Update Posted (Estimated): January 6, 2026
• Last Update Submitted That Met QC Criteria: December 31, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: cholangiocarcinoma, choledochal cysts, surgery
• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Digestive System Diseases; Biliary Tract Diseases; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma; Congenital Abnormalities; Cysts; Bile Duct Diseases; Digestive System Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cholangiocarcinoma; Choledochal Cyst
• Other Study ID Numbers: MorenoAsencioM

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No